World's Best Scientists 2026 revealed!
Lillian L. Siu

Lillian L. Siu

D-Index & Metrics

Medicine

D-Index
109
Citations
43565
World Ranking
5787
National Ranking
229

Overview

Lillian L. Siu is affiliated with the University of Toronto in Canada. Their research spans multiple interconnected areas within medicine, biochemistry, genetics, and molecular biology, with a primary focus on oncology and cancer-related studies.

Their work covers various subfields including:

  • Oncology
  • Cancer Research
  • Pulmonary and Respiratory Medicine
  • Molecular Biology
  • Otorhinolaryngology

Key research topics addressed in Siu's publications include:

  • Cancer Immunotherapy and Biomarkers
  • Cancer Genomics and Diagnostics
  • Lung Cancer Treatments and Mutations
  • Head and Neck Cancer Studies
  • CAR-T Cell Therapy Research
  • Colorectal Cancer Treatments and Studies
  • Pancreatic and Hepatic Oncology Research

Some of the recent papers authored by Siu include:

  • "Molecular profiling for precision cancer therapies", 2020, Genome Medicine
  • "Small molecules, big impact: 20 years of targeted therapy in oncology", 2020, The Lancet
  • "Circulating tumor DNA and liquid biopsy in oncology", 2020, Nature Cancer
  • "Personalized circulating tumor DNA analysis as a predictive biomarker in solid tumor patients treated with pembrolizumab", 2020, Nature Cancer
  • "Beyond immune checkpoint blockade: emerging immunological strategies", 2021, Nature Reviews Drug Discovery

Lillian L. Siu frequently collaborates with several researchers, including:

  • Anna Spreafico
  • Philippe L. Bédard
  • Aaron R. Hansen
  • Trevor J. Pugh
  • Scott V. Bratman

Their research is regularly published in prominent journals such as:

  • Journal of Clinical Oncology
  • Clinical Cancer Research
  • Cancer Research
  • Annals of Oncology
  • International Journal of Radiation Oncology*Biology*Physics

The breadth of Siu's published work includes over 600 contributions in medicine and nearly 200 in biochemistry, genetics, and molecular biology. The emphasis given to oncology and cancer research reflects their specialization.

Best Publications

  • Phase I and Pharmacologic Study of OSI-774, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Advanced Solid Malignancies

    Manuel Hidalgo;Lillian L. Siu;John Nemunaitis;Jinee Rizzo

  • Tumour heterogeneity in the clinic

    Philippe L. Bedard;Aaron R. Hansen;Aaron R. Hansen;Mark J. Ratain;Lillian L. Siu;Lillian L. Siu

  • Multicenter Phase II Study of Erlotinib, an Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck

    Denis Soulieres;Neil N. Senzer;Everett E. Vokes;Manuel Hidalgo

  • Dose Escalation Methods in Phase I Cancer Clinical Trials

    Christophe Le Tourneau;J. Jack Lee;Lillian L. Siu;Lillian L. Siu

  • Toward understanding and exploiting tumor heterogeneity

    Ash A Alizadeh;Victoria Aranda;Alberto Bardelli;Cedric Blanpain

  • Deintensification Candidate Subgroups in Human Papillomavirus–Related Oropharyngeal Cancer According to Minimal Risk of Distant Metastasis

    Brian O'Sullivan;Shao Hui Huang;Lillian L. Siu;John Waldron

  • Molecular profiling for precision cancer therapies.

    Eoghan R Malone;Marc Oliva;Peter J B Sabatini;Tracy L Stockley

  • Preliminary Results of a Randomized Study on Therapeutic Gain by Concurrent Chemotherapy for Regionally-Advanced Nasopharyngeal Carcinoma: NPC-9901 Trial by the Hong Kong Nasopharyngeal Cancer Study Group

    Anne W.M. Lee;W.H. Lau;Stewart Y. Tung;Daniel T.T. Chua

  • Small molecules, big impact: 20 years of targeted therapy in oncology.

    Philippe L Bedard;David M Hyman;David M Hyman;Matthew S Davids;Lillian L Siu

  • Circulating tumor DNA and liquid biopsy in oncology

    David W. Cescon;Scott V. Bratman;Steven M. Chan;Lillian L. Siu

  • Refining American Joint Committee on Cancer/Union for International Cancer Control TNM Stage and Prognostic Groups for Human Papillomavirus–Related Oropharyngeal Carcinomas

    Shao Hui Huang;Wei Xu;John Waldron;Lillian Siu

  • Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors

    M. Moore;H. W. Hirte;L. Siu;A. Oza

  • Randomized Trial of Radiotherapy Plus Concurrent–Adjuvant Chemotherapy vs Radiotherapy Alone for Regionally Advanced Nasopharyngeal Carcinoma

    Anne W. M. Lee;Stewart Y. Tung;Daniel T. T. Chua;Roger K. C. Ngan

  • Combining Gemcitabine and Capecitabine in Patients With Advanced Biliary Cancer: A Phase II Trial

    Jennifer J. Knox;David Hedley;Amit Oza;Ron Feld

  • Comparative prognostic value of HPV16 E6 mRNA compared with in situ hybridization for human oropharyngeal squamous carcinoma.

    Wei Shi;Hisayuki Kato;Bayardo Perez-Ordonez;Melania Pintilie

  • Enrollment of older patients in cancer treatment trials in Canada : why is age a barrier?

    Karen W L Yee;Joseph L. Pater;Lam Pho;Benny Chung-ying Zee

  • Future Directions in the Treatment of Neuroendocrine Tumors: Consensus Report of the National Cancer Institute Neuroendocrine Tumor Clinical Trials Planning Meeting

    Matthew H. Kulke;Lillian L. Siu;Joel E. Tepper;George Fisher

  • Personalized circulating tumor DNA analysis as a predictive biomarker in solid tumor patients treated with pembrolizumab

    Scott V. Bratman;Scott V. Bratman;S. Y. Cindy Yang;S. Y. Cindy Yang;Marco A. J. Iafolla;Marco A. J. Iafolla;Zhihui Liu;Zhihui Liu

  • Raf kinase as a target for anticancer therapeutics.

    Srikala S. Sridhar;David Hedley;Lillian L. Siu

  • Phase II Study of Lapatinib in Recurrent or Metastatic Epidermal Growth Factor Receptor and/or erbB2 Expressing Adenoid Cystic Carcinoma and Non–Adenoid Cystic Carcinoma Malignant Tumors of the Salivary Glands

    Mark Agulnik;Ezra W.E. Cohen;Roger B. Cohen;Eric X. Chen

Frequent Co-Authors

Gregory R. Pond
Gregory R. Pond McMaster University
Amit M. Oza
Amit M. Oza Princess Margaret Cancer Centre
Malcolm J. Moore
Malcolm J. Moore Princess Margaret Cancer Centre
Suzanne Kamel-Reid
Suzanne Kamel-Reid University Health Network
Brian O'Sullivan
Brian O'Sullivan Princess Margaret Cancer Centre
David W. Hedley
David W. Hedley Princess Margaret Cancer Centre
Fei-Fei Liu
Fei-Fei Liu Princess Margaret Cancer Centre
Bernard Cummings
Bernard Cummings Princess Margaret Cancer Centre
Janet Dancey
Janet Dancey Queen's University
John Douglas Mcpherson
John Douglas Mcpherson University of California, Davis

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

While studying Medicine in the USA can be competitive and demanding, there are alternative online pathways for those interested in healthcare careers. If you're already a registered nurse and looking to advance, consider exploring online nursing phd programs to reach the highest levels of leadership and education.

Those seeking a more affordable or flexible route to a nursing career can find a variety of cheapest online bsn programs that help fast-track advancement without leaving home. If you have a non-nursing bachelor’s degree, non nursing bachelor's to msn online programs provide direct admission to a Master’s in Nursing—perfect for career-changers in healthcare.

For those just starting out, online adn programs for non nurses offer accessible options to begin nursing studies, even without previous nursing experience. Exploring these online degree pathways can open doors to rewarding healthcare roles and help bridge the gap to clinical practice—often with more flexible schedules and lower costs than traditional medical school.

Best Scientists Citing Lillian L. Siu

Trending Scientists

Recently Published Articles